See more : Wavestone SA (0G1T.L) Income Statement Analysis – Financial Results
Complete financial analysis of Idorsia Ltd (IDRSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Idorsia Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- Allied Minds plc (ALLWF) Income Statement Analysis – Financial Results
- Dundas Minerals Limited (DUN.AX) Income Statement Analysis – Financial Results
- Adicet Bio, Inc. (ACET) Income Statement Analysis – Financial Results
- AirAsia X Berhad (5238.KL) Income Statement Analysis – Financial Results
- Kongsberg Gruppen ASA (KOG.OL) Income Statement Analysis – Financial Results
Idorsia Ltd (IDRSF)
About Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 152.39M | 97.10M | 35.35M | 71.76M | 23.82M | 60.62M | 158.09M | 0.00 |
| Cost of Revenue | 7.15M | 6.27M | 18.03M | 381.08M | 438.53M | 370.08M | 161.89M | 18.12M |
| Gross Profit | 145.24M | 90.84M | 17.32M | -309.32M | -414.71M | -309.47M | -3.81M | -18.12M |
| Gross Profit Ratio | 95.31% | 93.55% | 48.99% | -431.06% | -1,741.08% | -510.52% | -2.41% | 0.00% |
| Research & Development | 293.56M | 383.33M | 414.21M | 381.08M | 438.53M | 370.08M | 134.91M | 282.62M |
| General & Administrative | 380.02M | 509.03M | 233.67M | 63.00M | 66.44M | 60.64M | 30.95M | 40.20M |
| Selling & Marketing | 0.00 | 173.40M | 0.00 | 27.00M | 9.00M | 0.00 | -9.95M | 0.00 |
| SG&A | 380.02M | 509.03M | 233.67M | 90.00M | 66.44M | 60.64M | 21.01M | 40.20M |
| Other Expenses | -273.19M | 0.00 | 0.00 | 0.00 | -8.16M | -7.85M | -4.12M | 0.00 |
| Operating Expenses | 400.38M | 893.80M | 648.35M | 484.28M | 506.24M | 431.69M | 155.92M | 322.82M |
| Cost & Expenses | 407.53M | 900.07M | 648.35M | 484.28M | 506.24M | 431.69M | 165.97M | 322.82M |
| Interest Income | 16.11M | 48.00K | 6.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 20.67M | 17.17M | 27.94M | 9.05M | 8.16M | 0.00 | 0.00 | 13.37M |
| Depreciation & Amortization | 19.03M | 19.83M | 18.03M | 18.93M | 19.69M | 19.56M | 10.05M | 18.12M |
| EBITDA | -254.55M | -783.09M | -588.84M | -420.64M | -456.94M | -351.51M | 2.17M | -305.20M |
| EBITDA Ratio | -167.04% | -806.46% | -1,665.78% | -586.19% | -1,942.68% | -579.88% | 1.37% | 0.00% |
| Operating Income | -255.15M | -802.97M | -613.00M | -410.58M | -482.42M | -371.08M | -7.88M | -322.82M |
| Operating Income Ratio | -167.43% | -826.93% | -1,734.15% | -572.18% | -2,025.36% | -612.15% | -4.99% | 0.00% |
| Total Other Income/Expenses | -39.11M | -17.12M | -21.80M | -38.70M | -2.78M | -16.75M | -7.21M | -13.88M |
| Income Before Tax | -294.25M | -820.09M | -634.81M | -449.28M | -485.20M | -387.83M | -15.10M | -336.69M |
| Income Before Tax Ratio | -193.10% | -844.56% | -1,795.82% | -626.10% | -2,037.02% | -639.79% | -9.55% | 0.00% |
| Income Tax Expense | 3.67M | 7.81M | -210.00K | -4.16M | 9.45M | -314.00K | 186.00K | -2.05M |
| Net Income | -297.92M | -827.90M | -634.60M | -444.79M | -493.61M | -386.39M | -14.27M | -335.14M |
| Net Income Ratio | -195.50% | -852.60% | -1,795.23% | -619.85% | -2,072.33% | -637.42% | -9.03% | 0.00% |
| EPS | -1.67 | -4.67 | -3.77 | -3.11 | -3.71 | -3.06 | -0.12 | -2.81 |
| EPS Diluted | -1.67 | -4.67 | -3.77 | -3.11 | -3.71 | -3.06 | -0.12 | -2.78 |
| Weighted Avg Shares Out | 178.25M | 177.43M | 168.50M | 142.81M | 132.95M | 126.45M | 115.53M | 119.12M |
| Weighted Avg Shares Out (Dil) | 178.25M | 177.43M | 168.50M | 142.81M | 132.95M | 126.45M | 115.53M | 120.72M |
Invitation to Idorsia's Nine-Month 2023 Financial Reporting webcast and conference call
Idorsia reacquires the world-wide rights to aprocitentan
Idorsia Ltd (IDRSF) Q2 2023 Earnings Call Transcript
Idorsia announces financial results for the first half 2023 – adapting the company to create sustainable value
Idorsia announces a cost reduction initiative to be implemented by the end of 2023
Sosei Heptares - Investor and Press Conference on Today's Announcement Regarding the Acquisition and License Transaction with Idorsia
Sosei Heptares Acquires Idorsia's Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company
Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million
Invitation to Idorsia's HY 2023 Financial Results webcast and conference call
Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS
Source: https://incomestatements.info
Category: Stock Reports